The Anglo-Swedish biopharmaceutical company AstraZeneca has presented its report for 2024. The company’s total revenue increased by 21% last year, reaching $54.07 billion. The growth was due, among other things, to a 19% increase in sales, as well as increased cooperation in the field of drug production. Revenues and profits of OOO AstraZeneca Industries (the company’s Russian plant) also increased significantly. It showed the highest net profit since 2015, when the plant was launched in the Kaluga region.
OOO AstraZeneca Industries’ net profit reached 3,7 billion rubles, 1,5 times more than a year earlier, when the figure was 2,4 billion rubles. The company’s revenue for the year under review also increased 1,5 times, to 37,8 billion rubles. A proportional growth of the cost of sales brought them to 29,6 billion rubles. The profit from sales reached 7,1 billion rubles, gross profit was 8,1 billion rubles, and profit before taxes 4,8 billion rubles, Interfax writes.
OOO AstraZeneca Industries managed to reduce accounts payable from 19,5 to 18,9 billion rubles in 2024, while accounts receivable, on the contrary, increased from 20,4 to 26,8 billion rubles.
Earlier it became known that AstraZeneca has registered the cancer drug Datroway (datopotamab deruxtecan) in Russia for the treatment of non-small cell lung cancer and breast cancer. This drug is also present on the markets of other countries, but this is the first time it has been registered for this indication.
AstraZeneca develops and sells medicines for major diseases in areas including oncology, cardiovascular, gastrointestinal, infection, and neuroscience. The company operates in more than 100 countries and has 30 factories. The AstraZeneca Industries plant in Vorsino (Kaluga Region) was put into operation in October 2015. Investments in the project amounted to more than $224 million. Commercial production began in 2016. Today, the plant has a capacity of 40 million packages, or 850 million tablets per year.
